Andrew Callos, EVP, Chief Commercial Officer at CYTOKINETICS INC (CYTK), sold 3,618 shares at $62.44 ($226K) on 2025-12-29, disclosed to the SEC on 2025-12-30.
Scheduled sale ($226k) by EVP, Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.44 | 1,809 | $113K | 50.0% |
| 2 | $62.44 | 1,809 | $113K | 50.0% |
| Total | $62.44 avg | 3,618 | $226K | 100% |
| Filing → |
| CYTK | SELL | 2026-07-02 | $1.3M | — | Filing → |
| CYTK | SELL | 2026-06-01 | $1.1M | — | Filing → |
| CYTK | SELL | 2026-05-05 | $875K | — | Filing → |